Just Keep Rolling?—An Encompassing Review towards Accelerated Vaccine Product Life Cycles

Author:

Stiefel Janis1ORCID,Zimmer Jan1,Schloßhauer Jeffrey L.2,Vosen Agnes3,Kilz Sarah3,Balakin Sascha45ORCID

Affiliation:

1. Fraunhofer Institute for Microengineering and Microsystems IMM, Carl-Zeiss-Straße 18-20, 55129 Mainz, Germany

2. Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses IZI-BB, Am Mühlenberg 13, 14476 Potsdam, Germany

3. Fraunhofer Center for International Management and Knowledge Economy IMW, Neumarkt 20, 04109 Leipzig, Germany

4. Fraunhofer Institute for Ceramic Technologies and Systems IKTS Material Diagnostics, Bio- and Nanotechnology, Maria-Reiche-Straße 2, 01109 Dresden, Germany

5. Max Bergmann Center of Biomaterials (MBC), Technical University of Dresden, Budapester Strasse 27, 01069 Dresden, Germany

Abstract

In light of the recent pandemic, several COVID-19 vaccines were developed, tested and approved in a very short time, a process that otherwise takes many years. Above all, these efforts have also unmistakably revealed the capacity limits and potential for improvement in vaccine production. This review aims to emphasize recent approaches for the targeted rapid adaptation and production of vaccines from an interdisciplinary, multifaceted perspective. Using research from the literature, stakeholder analysis and a value proposition canvas, we reviewed technological innovations on the pharmacological level, formulation, validation and resilient vaccine production to supply bottlenecks and logistic networks. We identified four main drivers to accelerate the vaccine product life cycle: computerized candidate screening, modular production, digitized quality management and a resilient business model with corresponding transparent supply chains. In summary, the results presented here can serve as a guide and implementation tool for flexible, scalable vaccine production to swiftly respond to pandemic situations in the future.

Funder

Fraunhofer Society for the Advancement of Applied Research, Germany

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

Reference105 articles.

1. Deutsche Akademie der Naturforscher Leopoldina e.V., and German National Academy of Sciences (2023, May 30). Vaccine Development, Testing, and Approval. Available online: https://www.leopoldina.org/en/topics/vaccinations/vaccine-development-and-recommendations/.

2. Nord, L.B. (2023, July 26). Pharmamarkt in der Pandemie—Der Gewinner der Krise?. Available online: https://www.nordlb.de/meine-nordlb/download/research-dokument-10227?cHash=da511f96a0d59f1c338c0d55f59a5f34.

3. Statista (2023, July 26). Leading 10 Therapeutic Areas Worldwide by Sales in 2019. Available online: https://www.statista.com/statistics/407971/projected-revenue-of-top-therapeutic-areas-worldwide/.

4. VFA—Verband Forschender Arzneimittelhersteller, e.V (2023, July 26). Europas Impfstoffindustrie. Wir Versorgen die Welt—Verlässlich und Innovativ. Available online: https://www.vfa.de/download/faktenblatt-impfstoffindustrie-europa.pdf.

5. Frost & Sullivan (2023, July 26). Growth Opportunities in Global Vaccines Market, Forecast to 2024: Increased Investment in Adult Immunization and Improved Mammalian Cell-Culture Expression Systems will Drive Growth and Profitability ME98-52. Available online: https://store.frost.com/growth-opportunities-in-global-vaccines-market-forecast-to-2024.html.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3